Neogenomics, Inc.
NEO
$10.10
$0.323.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 187.80M | 181.33M | 168.04M | 172.00M | 167.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 187.80M | 181.33M | 168.04M | 172.00M | 167.82M |
| Cost of Revenue | 107.35M | 104.47M | 94.79M | 94.74M | 92.94M |
| Gross Profit | 80.45M | 76.86M | 73.25M | 77.26M | 74.88M |
| SG&A Expenses | 90.58M | 95.82M | 90.89M | 85.19M | 81.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 206.63M | 209.32M | 195.86M | 187.90M | 181.90M |
| Operating Income | -18.83M | -27.99M | -27.83M | -15.90M | -14.08M |
| Income Before Tax | -26.39M | -45.82M | -25.66M | -16.13M | -17.85M |
| Income Tax Expenses | 740.00K | -724.00K | 266.00K | -804.00K | -150.00K |
| Earnings from Continuing Operations | -27.13M | -45.09M | -25.92M | -15.32M | -17.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.13M | -45.09M | -25.92M | -15.32M | -17.70M |
| EBIT | -18.83M | -27.99M | -27.83M | -15.90M | -14.08M |
| EBITDA | -2.39M | -10.72M | -10.10M | 2.29M | 3.91M |
| EPS Basic | -0.21 | -0.35 | -0.20 | -0.12 | -0.14 |
| Normalized Basic EPS | -0.09 | -0.13 | -0.13 | -0.07 | -0.05 |
| EPS Diluted | -0.21 | -0.35 | -0.20 | -0.12 | -0.14 |
| Normalized Diluted EPS | -0.09 | -0.13 | -0.13 | -0.07 | -0.05 |
| Average Basic Shares Outstanding | 128.42M | 127.95M | 127.38M | 127.16M | 126.95M |
| Average Diluted Shares Outstanding | 128.42M | 127.95M | 127.38M | 127.16M | 126.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |